Horizon Discovery and Rosalind Franklin University to Develop Cystic Fibrosis Cellular Disease Models
Under the terms of the agreement, RFUMS will receive a perpetual academic research use license to the materials. Horizon will retain rights for commercial distribution of the cell lines to third parties, including biotech and pharmaceutical companies. Horizon also intends to develop, through its Horizon Diagnostics division, commercially available reference standards based on the modified cell line, for quality assessment of cystic fibrosis diagnostic tests. The project is funded through a grant awarded to Drs Neil Bradbury and Robert Bridges at RFUMS by Cystic Fibrosis Foundation Therapeutics Inc.
“Approval for the first CFTR therapeutic was recently granted by the FDA, however, fewer than 5% of patients carry the genetic profile for which this drug was approved. We hope that by creating this tool targeting the more common CFTR mutation, we can ultimately improve the lives of a far greater proportion of cystic fibrosis sufferers,” explained Dr Neil Bradbury, lead investigator at RFUMS. “Studies using non-human cell models have identified several, potential CFTR therapeutics from high-throughput screens. We hope to improve the efficiency of this process by creating a more informative screening tool with Horizon’s isogenic disease model cell lines, which we believe will also be useful for the broader research community.”
Most read news
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.